CTOs on the Move

Professional Gem Sciences Inc

www.progem.com

 
Professional Gem Sciences Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.progem.com
  • 5 S Wabash Ave Ste 1905
    Chicago, IL USA 60603
  • Phone: 312.920.1541

Executives

Name Title Contact Details

Similar Companies

biopharmservices

biopharmservices is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharsight Corporation

Pharsight Corporation is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Health Packaging

American Health Packaging is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.